Most Admired Companies of the Year 2026
Argá Medtech SA: Pioneering a Simpler Future for Atrial Fibrillation Treatment
![]()
At The Silicon Review, we recognize companies that challenge conventional thinking, address critical industry needs and shape the future through purposeful innovation. Argá Medtech SA, selected for our Most Admired Companies of the Year 2026 issue, exemplifies this through its mission to transform the treatment of atrial fibrillation (AF), the most common heart rhythm disorder.
Founded in 2020 by David Neale and Randy Werneth, Argá emerged from a clear unmet clinical need: patients with persistent AF often face lengthy, complex and costly procedures, while healthcare systems struggle to meet growing demand. Headquartered in Lausanne, Switzerland, with operations in San Diego, California, the company is building its vision around a straightforward principle: one adaptable tool, one streamlined workflow, and the ability to deliver the lesions each patient requires.
Argá’s investigational cardiac ablation system combines a dedicated generator using Coherent Sine-Burst Electroporation™ (CSE™) energy with the CSE™ Catheter. By adjusting an internal stylet, physicians can use the same catheter to isolate the pulmonary veins, create continuous lesion lines or treat targeted areas. The system is being developed for patients who may need more extensive lesion sets, including posterior wall isolation, with the aim of reducing device exchanges, procedural complexity and cost.
Its selection among the Most Admired Companies of the Year 2026 recognizes the ambition behind its work and its focused approach to a significant cardiovascular challenge. The CSE™ system is an investigational device and is not approved for sale in any market.
In conversation with David Neale,Co-Founder & CEO of Argá Medtech SA
You are developing a non-thermal cardiac ablation system using Coherent Sine-Burst Electroporation™ (CSE™), which uses sine waves rather than the square waves most pulsed field systems rely on. What has earned Argá Medtech the respect of the physicians you work with?
Respect is earned with results and candor, and three things resonate with the physicians we work with. First, a different way of delivering energy. Most pulsed field systems use square-wave pulses; our generator uses a sine wave, which allows better depth titration. The physician can match the energy to the thickness of the tissue being treated, which gives operators options rather than a one-size-fits-all dose. Second, workflow. One catheter is designed to complete the whole procedure, with no device exchanges and fewer steps for the team, so cases can be shorter, more predictable and easier to schedule. For a hospital, workflow is capacity, and capacity means more patients treated. Third, transparency: we share our clinical outcomes openly and are evaluating them in a US pivotal study. Physicians tell us that Argá listens, and we intend to keep it that way.
Your CSE™ Catheter is designed to combine the speed of a single-shot device with the flexibility of a focal catheter, simply by exchanging the stylet. How could that change the way ablation procedures are performed?
Until now, physicians often had to choose between a single-shot catheter, fast and efficient for the pulmonary veins, and a point-by-point catheter, flexible for everything else. Many patients, especially those with persistent AF, may need both, which means two devices, an exchange, more time and more cost. The CSE™ Catheter is designed to remove that choice. By changing the stylet, the same catheter shifts shape to create a circle, a continuous line or a focused point. Every exchange avoided saves time and takes a device off the bill. We see versatility not as a feature but as a philosophy: one patient, one catheter, the complete treatment that patient needs.
Thermal ablation carries risks of collateral injury, such as esophageal fistula and phrenic nerve palsy. How does your non-thermal approach address these concerns?
Traditional ablation uses heat or extreme cold, and that energy does not discriminate. It can injure nearby structures such as the esophagus or the nerve that controls the diaphragm, which is why physicians have spent decades guarding against rare but serious complications. Pulsed field ablation works differently: it targets heart muscle cells while largely sparing surrounding tissue, and our sine wave adds control by adjusting energy to the depth required rather than simply increasing it. In our
BURST-AF first-in-human study of 101 patients, we observed no esophageal injury, no phrenic nerve injury, no pulmonary vein stenosis, and no silent cerebral lesions in the 20 patients who had follow-up MRI. Trust is built on results like these, confirmed across many physicians and sites, which is what our pivotal study is designed to do.
Long-term success rates for AF ablation are often reported at between 40% and 80%. How is Argá Medtech working to improve outcomes?
AF can return for two reasons. The disease is progressive, and ablation treats its electrical pathways rather than its root causes, so some recurrence reflects the natural course of the condition. But a large share comes from the original procedure: incomplete lesions that leave gaps. That part we can improve. By matching energy to tissue depth and completing every lesion with one catheter, our system is designed to get it right the first time. In BURST-AF, remapping two to three months after treatment showed that 95.2% of pulmonary veins remained durably isolated. At one year, 91.2% of patients with paroxysmal (intermittent) AF and 82.8% with persistent AF remained free of atrial arrhythmia without antiarrhythmic medication. Our aim is to spare patients repeat procedures, and health systems the cost of treating the same patient twice.
Your BURST-AF results were presented at the 2026 AF Symposium, and the COHERENT-AF IDE study is underway. What role does clinical evidence play in how you build the company?
In medicine, a claim without evidence is just marketing. BURST-AF, our multinational first-in-human study of 101 patients, measured results the hard way, by remapping patients’ hearts months later rather than relying on symptoms alone. We presented the findings to the electrophysiology community at the 2026 AF Symposium. We then moved straight into COHERENT-AF, a pivotal study of up to 360 patients at sites in the United States and Europe. Enrollment reached the halfway mark in only four months, a clear sign that physicians want this option. We are targeting an FDA submission in mid-2027 and premarket approval in mid-2028. Integrity also means sharing what we learn, including what we would do differently.
AF is a growing global epidemic. How does your mission address the scale of that challenge?
More than 38 million people live with AF, yet only a fraction are ever offered ablation. The obstacles are not only medical; they are economic and structural: expensive labs, multiple proprietary systems, long procedures and too few specialists. To treat the epidemic rather than a privileged few, the procedure itself must become simpler, faster and less costly. That is our mission. In some cases, operators are already completing pulmonary vein isolation in 15 to 20 minutes, and our next-generation waveforms aim for less than 10. For persistent patients, the same catheter goes on to complete every additional lesion, with no change of device. Faster, simpler procedures mean more patients treated each day, treatment earlier in the disease when it works best, and care in efficient settings such as ambulatory surgery centers, where Medicare began covering cardiac ablation in 2026. Admiration, if it comes, should be for making great care sustainable, not exclusive.
What does the future hold for your company and its customers?
Our immediate priorities are clear: complete COHERENT-AF, file with the FDA and launch our AF system commercially in the US and Europe. Beyond that, the platform was built to grow. Because the sine wave can be titrated to tissue depth, we see natural extensions to more complex rhythm disorders, including ventricular tachyarrhythmias, which arise in the heart’s thicker lower chambers. We are equally committed to openness: our system is designed to work with the tools hospitals already own rather than lock them into another proprietary ecosystem. For hospitals, outpatient centers and physicians, that means a platform intended to lower the cost per patient instead of raising it. We will prove it with data.
|
Meet the leader behind Argá Medtech SA David Neale is Co-Founder and Chief Executive Officer of Argá Medtech. Over nearly 30 years in medical technology, he has held senior roles at Medtronic AF Solutions, LivaNova, Sorin Group and Baxter Healthcare, including full P&L leadership. His career has taken him across South America, Europe and the United States, and across multiple specialties, including cardiology and electrophysiology, renal therapies, neuromodulation and orthopedics. That breadth gives him a rare view of how different health systems adopt, pay for and struggle with innovation. Trained in pharmacy-biochemistry at the University of São Paulo, where he also earned his MBA, he co-founded Argá in 2020 with CTO Randy Werneth. Under his leadership the company closed an oversubscribed €54 million Series B, advanced to a US pivotal IDE study, and is working to take its AF application commercial by mid-2028. His conviction: innovation should uncomplicate care and reduce the burden on health systems, not add to it. |
“In medicine, a claim without evidence is just marketing.”
CAUTION: The CSE™ system is an investigational device. Limited by United States law to investigational use. Not available for sale in any market.